Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: Comparison of aspirin, warfarin, dabigatran, and rivaroxaban

Europace

Volumn 16, Issue 10, 2014, Pages 1443-1449

  Winkle, Roger A ^a,b   Mead, R Hardwin ^a,b   Engel, Gregory ^a,b   Kong, Melissa H ^a,b   Patrawala, Rob A ^a,b  

^a Silicon Valley Cardiology   (United States)

^b SEQUOIA HOSPITAL   (United States)

Author keywords

Ablation; Anticoagulation; Atrial fibrillation; Dabigatran; Rivaroxaban; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; DABIGATRAN; ENOXAPARIN; HEPARIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ABLATION CATHETER; ABLATION THERAPY; ADULT; ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; BRAIN ARTERY ANEURYSM; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; EMBOLISM PREVENTION; FALSE ANEURYSM; FEMALE; GASTROINTESTINAL HEMORRHAGE; GROIN HEMATOMA; HEART TAMPONADE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAPPING CATHETER; MORNING DOSAGE; NEUROLOGIC DISEASE; ORAL BLEEDING; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; AGED; ALGORITHM; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DEVICES; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATIONS; RADIOFREQUENCY RADIATION;

ADMINISTRATION, ORAL; AGED; ALGORITHMS; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; COMBINED MODALITY THERAPY; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; RADIO WAVES; THIOPHENES; THROMBOEMBOLISM; WARFARIN;

EID: 84928262912     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu196     Document Type: Article

References (24)

1. Calkins H, Brugada J, Packer DL, Capppato R, Chen S, Crijns H et al. HRS/EHRA/ ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. Europace 2007;9:335-79.
2. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, EstesMet al. 2011 ACCF/ AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011;8:157-76.
3. O'Neill MD, Wright M, Knecht S, Jais P, Hocini M, Takahashi Y et al. Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint. Eur Heart J 2009;30:1105-12.
4. Winkle RA, Mead RH, Engel G, Patrawala RA. Long term results of atrial fibrillation ablation: the importance of all initial ablation failures undergoing a repeat ablation. Am Heart J 2011;162:193-200.
5. Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009;6: 1425-9.
6. Wazni OM, Heheiry S, Fahmy T, Barrett C, Hoa S, PatelD et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio. Circulation 2007; 116:2531-4.
7. Schmidt M, SegersonNM, Marschang H, Akoum N, Rittger H, CliffordSMet al. Atrial fibrillation ablation in patients with therapeutic international normalized ratios. Pacing Clin Elecrophysiol 2009;32:995-9.
8. Page SP, Siddiqui MS, Finlay M, Hunter RJ, Abrams DJ, Dhinoja M et al. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance? J Cardiovasc Electrophysiol 2011;22:265-70.
9. Arshad A, Johnson CK, Mittal S, Buch E, Hamam I, Tran T et al. Comparative safety of peri-ablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study. Pacing Clin Electrophysiol 2014;37:665-73.
10. Raviele A, Natale A, Calkins H, Camm JA, Cappato R, Chen SA et al. Venice chart international consensus document on atrial fibrillation ablation: 2011 update. J Cardiovasc Electrophysiol 2012;23:890-923.
11. Winkle RA, Mead RH, Engel G, Patrawala RA. Safety of lower activated clotting times during atrial fibrillation ablation using open irrigated tip catheters and a single transseptal puncture. Am J Cardiol 2011;107:704-8.
12. Winkle RA, Mead RH, Engel G, Patrawala RA. Atrial fibrillation ablation using open irrigated-tip RF: experience with intraproceduralACT,210 seconds. Heart Rhythm 2014;11:963-8.
13. Bunch TJ, Crandall BG,Weiss JP, May HT, Bair TL, Osborn JS et al.Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol 2009;20:988-93.
14. Winkle RA, Kong MH. Peri-ablation warfarin vs. dabigatran: different but the same. Europace 2013;15:1385-6.
15. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15: 1407-11.
16. Abdulhak AAB, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwarlt KE et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2013;15:1412-20.
17. Steinberg BA, HasselbladV, Atwate BD, BahnsonTD,Washam JB, Alexander JH et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. J Interv Card Electrophysiol 2013;37:213-21.
18. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P et al. Feasibility & safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2013;63:982-8.
19. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2011;24: 264-8.
20. Winkle RA, Mead RH, Engel G, Patrawala RA. The use of a radiofrequency needle improves the safety and efficacy of transseptal puncture for atrial fibrillation ablation. Heart Rhythm 2011;8:1411-5.
21. Winkle RA, Mead RH, Engel G, Patrawala RA. Atrial fibrillation ablation: perpetual motion of open irrigated tip catheters at 50Watts is safe and improves outcomes. Pacing Clin Elecrophysiol 2011;34:531-9.
22. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation. Ciculation 2010;121:2550-6.
23. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012;5: 302-11.
24. Gomes T, MamdaniMM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. Can Med Assoc J 2013; 185:E121-7.